103 related articles for article (PubMed ID: 10216502)
1. Pharmacokinetic modelling of ifosfamide administered by continuous infusion on 5 days at the dose of 6 g/m2.
Passe P; Delepine N; Arnaud P; Urien S; Delepine G; Traoré F; Desbois JC; Brion F
Anticancer Res; 1999; 19(1B):837-42. PubMed ID: 10216502
[TBL] [Abstract][Full Text] [Related]
2. [High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients].
Baranzelli MC; Pichon F; Gourmel B; N'Guyen M; Deligny N; Demaille MC
Bull Cancer; 1997 Feb; 84(2):141-6. PubMed ID: 9180836
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.
Kerbusch T; Huitema AD; Ouwerkerk J; Keizer HJ; Mathôt RA; Schellens JH; Beijnen JH
Br J Clin Pharmacol; 2000 Jun; 49(6):555-61. PubMed ID: 10848719
[TBL] [Abstract][Full Text] [Related]
4. Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites.
Kerbusch T; Mathôt RA; Keizer HJ; Kaijser GP; Schellens JH; Beijnen JH
Drug Metab Dispos; 2001 Jul; 29(7):967-75. PubMed ID: 11408362
[TBL] [Abstract][Full Text] [Related]
5. [Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma].
Chen LK; Xu GC; Teng XY; Liang Y; Liu JL; Zhou XM
Ai Zheng; 2002 Aug; 21(8):903-6. PubMed ID: 12478904
[TBL] [Abstract][Full Text] [Related]
6. Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study.
Brain EG; Rezai K; Weill S; Gauzan MF; Santoni J; Besse B; Goupil A; Turpin F; Urien S; Lokiec F
Cancer Chemother Pharmacol; 2007 Aug; 60(3):375-81. PubMed ID: 17106751
[TBL] [Abstract][Full Text] [Related]
7. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
[TBL] [Abstract][Full Text] [Related]
8. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
[TBL] [Abstract][Full Text] [Related]
9. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion.
Boddy AV; Cole M; Pearson AD; Idle JR
Cancer Chemother Pharmacol; 1995; 36(1):53-60. PubMed ID: 7720176
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas.
Comandone A; Leone L; Oliva C; Frustaci S; Monteleone M; Colussi AM; Dal Canton O; Bergnolo P; Boglione A; Bumma C
J Chemother; 1998 Oct; 10(5):385-93. PubMed ID: 9822357
[TBL] [Abstract][Full Text] [Related]
11. [Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas].
Ishii T; Umeda T; Kitoh M; Tatezaki S; Satoh T
Gan To Kagaku Ryoho; 1993 Mar; 20(4):509-14. PubMed ID: 8452388
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children.
Boddy AV; Yule SM; Wyllie R; Price L; Pearson AD; Idle JR
Cancer Res; 1993 Aug; 53(16):3758-64. PubMed ID: 8339288
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide.
Kaijser GP; Keizer HJ; Beijnen JH; Bult A; Underberg WJ
Anticancer Res; 1996; 16(5B):3247-57. PubMed ID: 8920799
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach.
Kerbusch T; de Kraker J; Mathĵt RA; Beijnen JH
Clin Pharmacokinet; 2001; 40(8):615-25. PubMed ID: 11523727
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies.
Mougenot P; Pinguet F; Fabbro M; Culine S; Poujol S; Astre C; Bressolle F
Cancer Chemother Pharmacol; 2004 Jun; 53(6):503-12. PubMed ID: 15007638
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma.
Kerbusch T; Mathĵt RA; Keizer HJ; Ouwerkerk J; Rodenhuis S; Schellens JH; Beijnen JH
Eur J Clin Pharmacol; 2001 Sep; 57(6-7):467-77. PubMed ID: 11699611
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion.
Smith PF; Booker BM; Creaven P; Perez R; Pendyala L
J Clin Pharmacol; 2003 Dec; 43(12):1324-8. PubMed ID: 14615468
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.
Schneider CP; Merkel U; Grübner U; Kath R; Höffken K; Hoffmann A
J Cancer Res Clin Oncol; 2002 Jun; 128(6):313-8. PubMed ID: 12073049
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
